{"name":"SecuraBio","slug":"securabio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IPI-145","genericName":"IPI-145","slug":"ipi-145","indication":"Relapsed or refractory follicular lymphoma","status":"phase_3"}]}],"pipeline":[{"name":"IPI-145","genericName":"IPI-145","slug":"ipi-145","phase":"phase_3","mechanism":"IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival.","indications":["Relapsed or refractory follicular lymphoma","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPVUl5R0NNMlNqRGdXSnh3UzNxMXg4WW5LLW0tYjYwNU1iczF6UXlhMVRaTGtCMEpxSExXRk9zSU56bm9tc1c3UzJ6R283ZC1PS0M2ek1BU1RmV2dqRHowNzJ5M1g4bGNPWDR4dGJhSFp0Z2lSanQtNVViNXJnZHNNVDl2T05Gd0taOV9WS09KaVNocjBlZU1pNnp1TGptRjItLWYzcWVKamVTNDAtYjRvSk85OWRQN0NHdmJ0MkZ5S0NPRm05SWhVXzFGQlRBckhFWXRpbXN2Zjk0SzRkM19vNmZpWmZUWVdNSDRHVFd3bkxLbHd5MENpTHJPVkZnY3FXWDEzb1lRdDg4Z2_SAZACQVVfeXFMTmN6UXhwQlpJNlluOTFkdk1jbURBNVdBZlZ0b3d5NnM5TDFsWW96YlVRaGRUaVJDdjVDazNnbDBhNUhQVnpnLUYxQTI5RHpsZms1RW5tSVUtRmxCRlJpenN1OGhjVVU2MDRpYWdJS1JFWE1CZll0ZnZHcmVFbnBHVFNXMjNLdXVWa1VZUEJ4bE9URi1LZGZMbUxtb0tvVnV0NlpuZW1NOThrTlhWWnhiZzR2YnUydUFucmFleV9UR1VTRGZxYkdwbkRrRENlVnBvSzczSHJOeFlQb0prS2t3THRJUWxHR2xLTGVlUVhMd3R0WHFrVEZjbEdDZ2lvNGpoMGxyN1VQU2ZQTGQyR1VaZkI?oc=5","date":"2026-02-11","type":"pipeline","source":"The Manila Times","summary":"Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer - The Manila Times","headline":"Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOWmUySURWQUxkbS1fMjJWVWdkMEN4aHp2QU1lRVJjN0ZVNjRUNFZNMW1IMEFPN3JNQXpKX2QtTndXLXJGa0g1LXFsWW02aHVUYlJtZEJqNW4xcTJ2enFqaFRudUJNS1RwQURDcEJYTk1TVmtXWWlac0UyaW95V0pydWQ1NnJ0YkRUM3BjdmwyRE9qMHdfRGRhVnM5Q0pMb3ZXYi1MYXN2UDlZdWd0VTN5TTNhcEx5Q1ZNUFdNZ3MzY3FxX2RMd2c?oc=5","date":"2023-12-07","type":"pipeline","source":"PR Newswire","summary":"Secura Bio Announces the Addition of Two New Board of Directors Members - PR Newswire","headline":"Secura Bio Announces the Addition of Two New Board of Directors Members","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWV8zZkVsNHpWWlNrQXZjTUxyeVFnZHBxbTd2VXBRU1FyZzlBMHlBa2hIZlR2WDN6X0tJNTVnZnlKNG1LTDRqSnF1ekY1cmN5ald0UUoyTUdKbUdKdkM1UW9WdXFQZEtmUTA3ajNJT0FLdE9VdTlzYmpaYmQ1bHFSaA?oc=5","date":"2023-11-09","type":"trial","source":"Oncology Pipeline","summary":"Another PI3K inhibitor bites the dust | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Another PI3K inhibitor bites the dust | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQY2tiSGo4cDVDOWwwYnFzQzJQazN1c1k4NmtXZHY1ZnRUR3pxQkE4LTg2Tlc1WU9aVGZtelhQaGlzNzl0QUFMTFdwQjdIaTYtUHo4dkktbTZDMUR6X3g4N0xLZWlDYk1KZVVKeFpiT1V0VEt1RlVScjRNckZnWUJoZzdidVpsdzdaUnNySkY4MGtNbUpSYVZORHhOMi0yV2ZCTmZCZjY5alB1X2NaTml5Sg?oc=5","date":"2022-09-23","type":"regulatory","source":"Fierce Pharma","summary":"Copiktra's blood cancer nod in jeopardy as FDA experts vote down Secura's PI3K drug - Fierce Pharma","headline":"Copiktra's blood cancer nod in jeopardy as FDA experts vote down Secura's PI3K drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQRHJ5ZzVLUkJhclJwM0w3WnU1djhLLWhsM0JBR3YxMnRVcWlKNTM3QXRCeXhHaHUyVS1wemFkMDlSbW1xTGRycnIxY1A1WDlCUlliQ3NSaVgyTXJRQm9IY01nVXhwWVJVVFZwNmwxNVZwaHFJbWZ5MmxJLUIxMGRIT3hYNFVfUU40WEgzLTBxdHJRZFVmYkw5OWFhVFBCX001a1pLcmxGaFY2MVBZWHBjQTZUSUhNR2VNYldDWGR1MDE1NWhub3c?oc=5","date":"2022-01-26","type":"regulatory","source":"Fierce Biotech","summary":"Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit - Fierce Biotech","headline":"Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPRld4SXBXc2EySF96ZkRTTzRDX0tiVXZhWDRNYmpmZ1h3eUpQcEN0bUFkelI1U29PMUlvTlJ4dkl6c1lnc3A4eU5NMDUtZWMzQ0tkNllkaW1pbm5ORkZtRzRodWtlZ1pYbDV0MlZIalo3WWNzYmNVdWJfNWR5R3JBNDBuVDR1d0t5XzBWQUxMNDNWbkFUUGI4cWNWNmZCQnpQQWxEOW5DbEVEczMzd3F6RGFzUWhGUEZEVzlhWGh2SWhLWmZZVTdrZVhUM0p4a1phbXBYRlBWRFRCQTFXajJrWlZMd2lxT1JucEZRM2lkT2FzdGNMZ1dPQWRZR196aXdNaUd0bDBfWklFSXd0bW8xN0hFcTFTMkU1bFpsLTlJcWdiMnVTMHRWSmlnZ0NtTGEzdVZCS3dkN1M5ejl4TE5ucw?oc=5","date":"2021-12-03","type":"pipeline","source":"PR Newswire","summary":"Secura Bio Announces Copiktra® (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication - PR Newswire","headline":"Secura Bio Announces Copiktra® (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOODFpdGVMMGhjbTRCUmtxazY0emxGdmxmTkF2em8zbVZkdkN2Ny1PRzJ5eTU1YlJOSXhGd2FqbVJmN296Tm9HOWc2dHc1WkN4ZzBpbTgtR1VKZ3BPNF9FekNFRzhVZVBtWTJDTmZNNVB1V3FwcXlVZ2s1MTVNdEVFbVVicF9qbFIyODdocURINmhJUEJaSnphWkFIeFZJNEpNbEtpaGdNNnpWQnpUMkc4UkRRa1BjT2xYeHJN?oc=5","date":"2021-11-30","type":"pipeline","source":"PR Newswire","summary":"Secura Bio Announces U.S. Withdrawal of FARYDAK ® (panobinostat) NDA - PR Newswire","headline":"Secura Bio Announces U.S. Withdrawal of FARYDAK ® (panobinostat) NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQa1VlMENOQmU4Zl9ZbnhZZ1FpT09aSmVpTG5CQ1hwSFRGd2s2TmFRcHVxUUc5cHpfbXVPSGlOTVB3ekxkYXZ0Q09DaDJHckRZelNhREFKSG9NVTU1ekhwNi1HaWlycWhoSnRYeUJwUy1OdVh5NTIxWXE3ODl5THZnZ0tTU1pBaktzaVJ0MWVoNTlwcDBEcFlfaXB4bVNJNUVGM2kxYV9Ba1hEQUNVSzc5TzhYMmdCODZvVHlVNGRlX21aVmwyNkJuUDV1bDdkVFZlb3BFc1ZvOXl5b1Q1UVdqRmMtUGFCdVpKY1E?oc=5","date":"2021-09-22","type":"pipeline","source":"PR Newswire","summary":"Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited - PR Newswire","headline":"Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQbktueU10VUxkX2hHU2JZZWhrbl81ZXNtWWV1ekVlVUYxVHpHQVUtcVVySHQwblVFeEl3QzNJNHhyN2tMbC1BcjNLdEpOSGJyZS1yQ3FEbTN5WGRyWlZBTTAxVnBhYWNNVWQ1SnVkem9wNkRqM3ZGWjMyWHlHOXNlblh3?oc=5","date":"2020-08-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Verastem to divest Copiktra rights to Secura Bio for up to $381m - Pharmaceutical Technology","headline":"Verastem to divest Copiktra rights to Secura Bio for up to $381m","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}